Recurrent acute coronary syndrome after infliximab infusion in a patient with rheumatoid arthritis: Case report.
Martin Rebolledo-Del ToroCamila BordaLuisa Fernanda RincónAndrea CastilloDaniel Gerardo Fernández-ÁvilaPublished in: Colombia medica (Cali, Colombia) (2023)
Patients with rheumatoid arthritis have subclinical cardiovascular disease and increased cardiovascular risk. The evidence regarding the relationship between infliximab and ischemic heart disease is controversial. A wide clinical spectrum of cardiac involvement with infliximab infusion is found in case reports, ranging from stable angina to ST-segment elevation acute coronary syndrome. The pathophysiology is not elucidated, with hypotheses proposing plaque rupture, allergic reactions, and vasoconstriction as possible disease mechanisms. The direct association between infliximab infusion and acute coronary syndrome needs more clinical research to optimize the management and prognosis of patients presenting with this type of complication.
Keyphrases
- acute coronary syndrome
- case report
- percutaneous coronary intervention
- ulcerative colitis
- antiplatelet therapy
- cardiovascular disease
- rheumatoid arthritis
- low dose
- coronary artery disease
- left ventricular
- coronary artery
- heart failure
- metabolic syndrome
- cardiovascular risk factors
- cardiovascular events
- systemic sclerosis
- atopic dermatitis